Castle Biosciences Announces First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Castle Biosciences Inc. (CSTL) Tops Q1 EPS by 6c
May 10, 2021 4:51 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q1 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $16.72 million.
We are pleased with our strong execution in the first quarter, with revenue increasing by 31% over the first quarter of 2020, said Derek Maetzold, president and chief executive officer of Castle Biosciences. In-line with our expectations, January and February were impacted, we believe, by COVID-19 and weather interruptions. However, we are encouraged by the positive trends that we are seeing. Specifically, we saw order volume for... More
